News | September 07, 2021
Indian Pharmaceutical Market grew by 17.7 per cent in August
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
The company has been sold to Shinshin Pharmaceuticals
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
Subscribe To Our Newsletter & Stay Updated
